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Summary 
Mice carrying  large  established  major  histocompatibility  complex  (MHC)  class  I §  sarcoma 
tumors can be successfully treated by immunization  with genetically engineered sarcoma cells 
transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more 
effective than previously described strategies using cytokine- or B7-transduced tumor cells which 
are only effective against smaller tumor loads, and which cannot mediate regression of longer- 
term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 
molecules are coexpressed on the same tumor cell.  Immunity induced by immunization  with 
class II +  B7-1 §  sarcoma cells involves CD4 + and CD8 + T cells, suggesting that the 
increased effectiveness  of the transfectants is due to their ability to activate both of these T  cell 
populations. 
A  number  of different  approaches  have  recently  been 
developed to generate vaccines against tumors.  Many 
of these approaches are based on genetically engineering tumor 
cells so they are more "immunogenic" and thereby stimulate 
the generation of tumor-specific effector cells. Some of these 
engineered tumor cells provide cytokines that bypass the need 
for helper cells (reviewed in reference 1), while others pro- 
vide costimulatory signals for direct stimulation  of CD8 + 
T cells (2, 3) or CD4 + T cells (4). In almost all cases, tumor 
cells that are genetically modified to secrete certain cytokines 
or to present costimulatory signals  are themselves rejected 
by the autologous host, and are effective vaccines against sub- 
sequent  challenge  with  wild-type  tumor.  Although  such 
modified  tumor  cells  are effective immunogens  when  ad- 
ministered before challenge with wild-type tumor, their effec- 
tiveness in mediating rejection of large or long-term preex- 
isting tumors has  not been established. 
In the present report we describe an immunization strategy 
that is highly effective in mediating regression of established 
mouse sarcoma tumors. Our approach is designed to enhance, 
rather than bypass, the generation of tumor-specific Th lym- 
phocytes, and relies on the premise that activation of T cells 
requires  the delivery of antigen-specific and costimulatory 
signals  from the APC (5). Inasmuch  as tumor peptides are 
the most likely targets for tumor-specific T  cells,  we have 
reasoned that MHC class I § tumor cells should be adequate 
targets  for MHC-restricted  effector lymphocytes, and that 
if provided with the appropriate restriction  elements,  they 
should also function as APC to class  II-restricted  Th lym- 
phocytes. We have therefore transfected class I + mouse SaI 
sarcoma cells with genes encoding syngeneic MHC class II 
plus B7-1 (previously called B7) costimulatory molecules and 
used the transfectants as immunogens for stimulating tumor- 
specific immunity. 
Materials and Methods 
Mice.  Male and female A/J and nude mice of 6-10 wk of age 
were purchased from The Jackson Laboratory, Bar Harbor,  ME, 
or bred in the University of Maryland Baltimore County animal 
facility. 
Cells and Transfections.  SaI, SaI/N, and all transfectants were 
maintained in culture as previously described (4, 6). Transfections 
were performed  as previously described (6)  using  SaI/A  k done 
19.6.4 (6) or SaI. Cells were transfected with pSV2hph plasmid 
plus B7-1 cDNA (7). Bulk SaI/Ak/B7-1 transfectants were selected 
in 400 gg/ml hygromycin plus 400 #g/ml G418; SaI/B7-1 trans- 
fectants were selected in 400 gg/ml hygromycin. All lines were 
cloned at least once by limiting  dilution.  In some cases, B7-1 ex- 
pression decreased  with time in culture. These clones were recloned 
to obtain stable B7-1 expression. All transfectants used in this study 
are independent  clones. 
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I-Ak-specific mAb (8).  1G10 is a rat IgG2a B7-1-specific  mAb (7). 
GK1.5 is a rat IgG2a CD4+-specific rat mAb (9). 2.43 is a rat IgG 
CDS+-specific rat  mAb (10).  20-8-4 is a mouse IgG2a H-2K  b- 
specific mAb (11). Antibodies were protein A or protein G purified 
and used as previously described (4, 6). 
Tumor Challenges.  Ascities tumor challenges (SaI and deriva- 
tives) were performed as previously described (6). Mice were visually 
checked three times/wk for tumor growth, and when they became 
moribund they were killed. Tumor incidence is the number of mice 
with nonregressing tumors/total number of mice inoculated.  In 
previous studies we have reported mean survival times rather than 
tumor incidence.  Recent Institutional Animal Care and Use Com- 
mittee (IACUC) regulations prohibit "survival to death" studies, 
hence we have changed end-points to measure tumor incidence. 
Solid tumor challenges (SaI/N) were given subcutaneously in the 
flank.  Tumor diameters were measured three times/wk and the 
tumor volume determined by the formula "tl'r  3. A tumor volume 
of 100 mm  3 is approximately equal to a tumor diameter of 6-7 
mm. Mice reported as tumor-free did not have palpable tumors 
as long as they were maintained in our animal colony.  The obser- 
vation period for tumor incidence ranged from 53 d to 6 mo post- 
tumor challenge, depending on the experiment. In our experience, 
mice challenged with either the ascites or solid SaI line that were 
tumor-free I mo after challenge remained tumor-free indefinitely. 
Mice challenged with 10s-106 wild-type SaI or SaI/N cells devel- 
oped ascites  or solid tumors within  ~12-18  and 5-15 d, respec- 
tively. SaI-challenged mice became moribund with ascites  tumor 
within ~20-28 d  (6).  Mice challenged with  10s-106 SaI/N cells 
became moribund with large (>3 cm diameter) solid tumors by 
~35-50  d  after tumor challenge. 
Immunofluorescence and Flow Cytometry.  Immunofluorescence 
staining and flow cytometry analyses were performed as previously 
described using an Epics C flow cytometer (Coulter Corp., Epics 
Div., Hialeah, FL) (6). 
In  Vivo T Cell Depletions.  Mice were depleted for CD4 + T 
cells (GK1.5 mAb ascites) or CD8 + T cells (2.43  mAb ascites) as 
previously described (4).  Ascites of the mouse mAb 20-8-4 (11) 
was used as an irrelevant antibody control. Briefly, mice were inoc- 
ulated with  100/~1 of ascites  fluid  of the relevant mAb on days 
-6, -3, and -1 before tumor challenge (naive mice), or before treat- 
ment with SaI/Ak/B7-1 cells (mice carrying established tumor), 
and twice a week after tumor challenge until mice died of tumor, 
or until they became moribund, or until tumors became excessively 
large (usually 20-28 d after tumor challenge). Fluorescence anal- 
ysis of splenocytes of treated mice demonstrated <3-5% or ~1% 
of the normal level of CD4 + or CD8 + T  cells,  respectively. 
Histopathology.  Tumors were excised and fixed in 4% formalin, 
embedded in paraffin,  sectioned, and stained with hematoxylin and 
eosin. 
Results 
The  mouse  sarcoma  I  tumor  is  a  methylcholanthrene- 
induced  fibrosarcoma  of A/J  (H-2  a)  strain  mice.  The  SaI 
variant grows progressively as an ascites tumor when inocu- 
lated intraperitoneally,  while the  SaI/N variant  grows as a 
solid tumor when inoculated subcutaneously. The wild-type 
tumor cells constitutively  and  stably express MHC  class I 
molecules (Kk,Da,Ld),  and do not express MHC  class II or 
costimulatory molecules. In previous studies we have demon- 
strated that SaI cells transfected with  syngeneic MHC  class 
II genes  (SaI/A  k cells)  are rejected  by A/J  mice  and  are  a 
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Figure  1.  Immunofluorescence flow cytometry profiles of SaI sarcoma 
cells stained for MHC class II I-A  k and B7-1 molecules. Cells were stained 
by indirect immunofluorescence with  mAb to  I-A  k (10-3-6; 8)  plus 
GAMIgG-FITC (a-i), or mAb to B7-1 (1G10; 7) plus GAratlgG-FITC 
0-r). Dotted lines are staining of fluorescent conjugate without mAb; solid 
lines are staining with mAb plus fluorescent conjugate. Mean channel 
fluorescence for each clone is shown in the upper right-hand corner of 
each panel. The x axis represents three log cycles of fluorescence intensity. 
highly efficient vaccine against later challenge with wild-type 
class II- tumor (6). Such transfectants must express the cy- 
toplasmic domain of the class II heterodimer (12), or constit- 
utively express the B7-1 costimulatory molecule (4). Because 
of the potent immunogenicity of SaI transfectants expressing 
truncated  MHC  class II molecules plus B7-1 molecules we 
have speculated that SaI sarcoma cells expressing full-length 
class II molecules plus B7-1 costimulatory molecules may be 
highly efficient immunogens in tumor-bearing mice (4). To 
test this hypothesis, we have generated transfectants that stably 
express both  syngeneic MHC  class II and B7-1  molecules, 
and compared them to tumor cells expressing B7-1 without 
MHC  class II. 
Generation of SaI/B7-1  and  SaI/Ak/BT-1  Sarcoma Cells. 
The ascites variants SaI and SaI/A  k cells were cotransfected 
620  Immunotherapy of Established Tumors with the pRcCMWB7-1 plasmid plus the pSV2hph plasmid 
to yield transfectants expressing B7-1 alone (SaI/B7-1 trans- 
fectants) or  syngeneic MHC class II plus B7-1 molecules 
(SaI/Ak/B7-1  transfectants). Transfectants  were screened by 
flow cytometry and cloned by limiting dilution one to three 
times. Fig. 1 shows flow cytometry profiles of wild-type SaI, 
class II + SaI/A  k clone 19.6.4,  SaI/B7-1  clones 5 and 36, and 
SaI/Ak/B7-1  clones 1, 2, 12 stained for I-A  k and B7-1 mole- 
cules. Although the intensity of staining for B7-1 and I-A  k 
varies somewhat for the various transfectants, the mean channel 
fluorescence is between 72 and 172 for B7-1 and 101-192 for 
I-A  k.  All of these lines  have comparable levels of endoge- 
nously encoded MHC class I K k and D a molecules (data not 
shown). These transfectants have been maintained in vitro 
for several months, demonstrating their stable expression  of 
MHC class II and B7-1 molecules. 
Sarcoma Transfectants Ex~essing B7-1 Alone orB7-1 plus MHC 
Class II Are Rejected by Autologous A/J Mice.  We have pre- 
viously reported that SaI sarcoma cells expressing truncated 
MHC class II heterodimers plus B7-1 costimulatory mole- 
cules are rejected by autologous A/J mice (4). Simultaneously, 
Table  1.  Sarcoma Cells Expressing Transfected B7-1 and~or 
MHC Class II Genes Are Rejected by Autologous Mice 
Tumor  Tumor 
Challenge tumor  dose  incidence* 
SaI  10  s  5/5 (25 d) 
106  5/5 (21 d) 
SaI/Ak/B7-1.1  106  0/5 (>53 d) 
SaI/Ak/B7-1.2  106  0/5  (>6 mo) 
SaI/Ak/B7-1.12  106  0/10 (>2 mo) 
5  ￿  l&  0/2 (>2 mo) 
SaI/Ak/B7-1.2 multiple  106  0/5  (>6 mo) 
injections 
SaI/ A k  /B7-1.12  multiple 
injections 
SaI/B7-1.5 
SaI/B7-1.36 
SaI/B7-1.36 multiple 
injections 
106  0/5 (>6 mo) 
5  x  10  s  0/5 (>37 d) 
5  x  10  s  1/10 (>5 mo) 
106  1/15  (>2.5 mo) 
2  x  106  3/11  (>2.5 too) 
6  x  106  0/2 (>3 too) 
106  0/10 (>50 d) 
Autologous A/J mice were challenged  intraperitoneally  with the indi- 
cated tumor  cells  and followed  for tumor  incidence  as described  in Materials 
and Methods. Multiply  injected mice were given the indicated  number 
of cells per injection  at 7-10-d intervals for a total of four to five  injec- 
tions. Tumor incidence  is the number of mice with tumors/total num- 
ber of mice injected. 
* Number in parentheses indicates how long after tumor challenge the 
mice were followed for tumor incidence. 
other investigators have reported that K1735 melanoma cells 
transfected with B7-1 are rejected by autologous C3H mice 
(2,  3).  To confirm these studies,  we have challenged A/J 
recipients intraperitoneally with a range of tumorigenic doses 
of three independent SaI/Ak/B7-1  clones  and 2  SaI/B7-1 
clones,  and followed them for tumor incidence.  A/J mice 
have also been challenged four to five times at 7-10-d intervals 
with SaI/Ak/B7-1  clones 2 and 12,  and SaI/B7-1 clone 36 
to determine if exposure to multiple inoculations is tumori- 
genic. As shown in Table 1, none of the clones of either trans- 
fectant forms tumors in the autologous host at doses ranging 
from 10  s to 6  x  106 tumor cells per mouse. These results 
confirm the observations that expression  of B7-1  increases 
the immunogenicity of tumor cells and results in rejection 
of the transfectants. 
Transfected Tumor Cells Expressing B7-1 + or Class II + and 
B7-1 + Molecules Induce Protective Immunity.  The B7-1 mol- 
ecule is required for the activation of T  cells, but it is not 
required on the target cell for recognition by effector cells 
(13, 14). We have therefore inoculated autologous A/J mice 
with  two  different  doses  of  SaI/AUB7-1  or  SaI/B7-1 
tumors, and 1-6 mo later challenged them with wild-type 
SaI ascites or SaI/N solid tumor cells. Tumor-challenged  mice 
were observed for tumor incidence at least twice a week for 
2-6 mo after tumor challenge.  As shown in Table 2,  three 
independent clones of SaI/AUB7-1 and two clones of SaI/ 
B7-1 cells are potent immunogens against subsequent chal- 
lenge of wild-type ascites (SaI) and/or solid (SaI/N) tumor, 
Table 2.  Expression of Transfected MHC Class II and~or B7-1 
Genes Confers Protective Immunity 
Immunizing  Challenge tumor 
tumor  (dose)  Tumor incidence* 
-  SaI  (10 s  or  106)  10/10  (25  d) 
-  SaI  (5  x  106)  5/5  (23  d) 
--  SaI/Y (105)  9/10 (45 d) 
--  SaI/N (10 6)  9/9 (42 d) 
SaI/Ak/B7-1.1  SaI  2/5 (>6 mo) 
SaI/Ak/B7-1.2  SaI  0/5 (>3.5 mo) 
SaI/Ak/B7-1.12  SaI  0/15 (>5.5 mo) 
SaI/Ak/B7-1.12  SaI/N  (106)  0/5 (>8 mo) 
SaI/B7-1.5  SaI  1/5 (>42 d) 
SaI/B7-1.36  SaI  0/27 (>48 d) 
SaI/B7-1.5  SaI/N (105)  0/4 (>42 d) 
SaI/B7-1.36  SaI/N (10  s)  0/4 (>5 mo) 
A/J mice were immunized  intraperitoneally  with 10s-106 live tumor cells 
and challenged  1-6 mo later with SaI tumor (i.p.) or Sal/N tumor (s.c.). 
Challenge tumor doses are 5 x 106 cells unless  noted  otherwise. Tumor 
incidence is the number of mice with tumors/total number of mice in- 
jected. 
* Number in parentheses indicates how long after tumor challenge  the 
mice were followed for tumor incidence. 
621  Baskar  et al. while unimmunized mice are highly susceptible. At the doses 
tested, class II+B7-1 + and B7-1 + tumor cells are therefore 
equivalent in their ability to immunize naive mice against 
later challenges of unmodified tumor given as long as 6 mo 
after immunization. 
SaI/Ak/B7-1  Cells, but not SaI/B7-1  Cells, Rescue Mice Car- 
rying Established  Tumor.  Because of the potent protective im- 
munity induced by the B7-1 transfectants, we have tested if 
the transfectants could be used as therapeutic reagents to treat 
A/J mice carrying established  solid sarcoma tumor.  This 
strategy is based on the assumption that mice carrying estab- 
lished tumors are not adequately stimulated by tumor pep- 
tide to mediate tumor rejection. If, however, the tumor-beating 
host's immune system is optimally activated, then the resulting 
immune response may mediate partial or complete tumor 
regression. 
To test the ability of the B7-1 transfectants to stimulate 
immunity in tumor-bearing mice, autologous A/J mice were 
inoculated subcutaneously in the flank with 105 SaI/N cells, 
and 13 d later given a single intraperitoneal inoculation of 
106 SaI/Ak/B7-1  cells. Solid tumors were palpable  at the in- 
jection site by days 5-7, and at the time of SaI/Ak/B7-1 ad- 
ministration SaI/N tumors were hard, solid, palpable masses 
of 2-5 mm in diameter. Histology of 10-d established tumors 
indicates that as early as 10 d after inoculation the malignant 
sarcoma tumors are highly invasive (Fig. 2 A), vascularized 
(Fig.  2, A  and B),  and contain areas of necrotic tissue,  as 
well as mitotic tumor cells  (Fig.  2  C). 
As  shown in Fig.  3 A,  A/J mice  not inoculated with 
SaI/Ak/B7-1  cells developed  progressively growing SaI/N 
tumors that reached  a diameter of '~2-3 cm and ulcerated 
by days 40-50.  Of five A/J mice given a single injection of 
SaI/Ak/B7-1  clone 12 on day 13, however, the SaI/N tumors 
of three mice completely regressed,  and the tumors of the 
two other mice were growth arrested (Fig. 3 B). In a similar 
experiment, three out of five mice showed regression of es- 
tablished SaI/N  solid  tumors after a single  inoculation of 
SaI/Ak/B7-1  clone 2  on  day 13  after initiation of SaI/N 
growth (data not shown). To determine the effect of the com- 
bination of B7-1 plus class II expression versus B7-1 expres- 
sion alone,  we have tested SaI/B7-1  cells in the same  ex- 
perimental protocol. As shown in Fig. 3  C, an equivalent 
dose of SaI/B7-1 cells has little, if any, effect on the growth 
of established SaI/N tumors. Likewise, inoculation of SaI/A  k 
cells not transfected with the B7-1 gene does not alter the 
growth of established SaI/N tumors (Fig. 3 D). Tumor cells 
transfected with MHC class II plus B7-1 genes are therefore 
efficient therapeutic agents for controlling wild-type tumor 
Figure  2.  Histology  of SaI/N tumors. Palpable tumors were excised  from A/J mice 10 d after inoculation  and prepared as described in Materials 
and Methods.  A shows  sarcoma  tumor  (right and center) interdigitating  into  normal  skin  epithelium  (left  side  of  panel) (x 100). B shows  a higher  magnification 
(x250) of a blood vessel immeshed  within the sarcoma  tumor. C shows a necrotic region of the tumor (left side) and numerous  mitotic  tumor cells 
(center and right). * Denotes a blood vessel; ~  denotes mitotic cells; N denotes necrotic region. 
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Figure  3.  Inoculation of SaI/Ak/B7-1 
cells into mice carrying 13-d established SaI 
tumors causes tumor regression.  A/J mice 
were inoculated  subcutaneously  in the flank 
on day 0 with 105 wild-type  SaI/N tumor 
and left untreated  (A) or 13 d later given 
a single intraperitoneal injection of 2  x 
106 SaI/Ak/B7-1.12  cells (B), 106 Sal/B7- 
1.36 cells (C), or 2 x 106 SaI/A  k cells (D). 
Each line  represents  growth of an individual 
solid tumor  in an individual  mouse. Cured 
mice remained tumor-free for the 2.5-7- 
mo observation period after SaI/N chal- 
lenge. A second  clone  of SaI/Ak/B7-1 cells 
(clone 2) gave  similar  results  as those  shown 
in/~ 
growth in a significant percentage of animals carrying long- 
term established  solid sarcomas. 
Mice carrying larger solid tumors have also been treated 
with SaI/Ak/B7-1 cells. Autologous A/J hosts were inocu- 
lated subcutaneously in the flank with 106 SaI/N cells, and 
given SaI/AUB7-1 clone 12 cells intraperitoneally 9 d later. 
At the time of SaI/AVB7-1  inoculation, the mice had SaI/N 
tumors ranging in size between 4 and 7 mm in diameter. 
As shown in Fig. 4 A, untreated mice developed progressively 
growing tumors. Mice treated with SaI/Ak/B7-1 cells on day 
9, however, showed a significant delay in SaI/N tumor growth, 
and two out of five of the mice showed complete tumor 
regression (Fig.  4 B).  Similar  delay in tumor growth and 
regression  was seen when SaI/Ak/B7-1  cells were given 9 d 
after challenge with 3  x  105 SaI/N tumor (Fig.  4 C  [un- 
treated]  vs. Fig. 4 D  [given SaI/AUB7-1 clone 2 on day 9]) 
or  13  d  after challenge with  106  SaI/N  tumor  (data not 
shown). SaI/B7-1 cells have also been tested for their abilit)) 
to mediate tumor regression in animals inoculated with the 
higher SaI/N dose. A/J mice given 106 SaI/N cells on day 0, 
and treated with a single injection of SaI/B7-1 cells on day 9, 
do not have reduced tumor burdens relative to untreated mice 
(Fig. 4, F vs E). Larger SaI/N established  tumors therefore 
also regress after SaI/Ak/B7-1  treatment, while inoculation 
of SaI/B7-1 cells has no significant effect on growth of estab- 
lished high or low dose SaI/N  tumors. 
Multiple Inoculations of Transfected Tumor Cells Are no More 
Effective than a Single Inoculation.  We next investigated if mul- 
tiple injections of SaI/B7-1 cells could cause regression of 
established  SaI/N tumor. A/J mice were given 3.3  x  105 
SaI/N  cells  s.c. on day 0  and subsequently inoculated in- 
traperitoneally with SaI/B7-1 clone 36 cells on days 2,  11, 
623  Baskar  et al. 
14, 23, 32, and 42. As shown in Fig. 5, no effect on SaI/N 
tumor growth is seen in mice given multiple inoculations 
of SaI/B7-1 cells, even if the first inoculation is given as early 
as day 2 after the initial tumor challenge (Fig.  5, B vs A). 
We have  also  tested if the therapeutic potency of SaI/ 
Ak/B7-1  transfectants is improved if multiple inoculations 
of transfected cells are given. A/J mice were given 106 SaI/N 
tumor cells s.c. in the flank on day 0, and inoculated 10, 15, 
31, and 42 d later with SaI/Ak/B7-1  clone 2 cells. As shown 
in Fig.  5 D  multiple dosing with SaI/Ak/B7-1  cells cures 
two out of five mice and significantly delays SaI/N tumor 
growth in the remaining three out of five mice (compare to 
Fig. 5 C). However the effect is not significantly better than 
that  seen  with  a  single  inoculation of SaI/Ak/B7-1  cells 
(compare  to Fig.  4 B). 
SaI/B7-1 cells therefore have no effect on growth of estab- 
lished tumors even if administered in multiple doses, while 
SaI/Ak/B7-1  cells have an equal therapeutic effect if they are 
given as a single dose or as multiple inoculations. 
Table 3 summarizes the therapeutic ef~cacy of the various 
SaI/Ak/B7-1  and SaI/B7-1 clones  that have been tested for 
their ability to curtail the growth of established SaI/N sar- 
comas. Because the dose of therapeutic cells administered does 
not affect therapeutic efficacy, and because individual clones 
do not behave differently, we have pooled the results of inde- 
pendent clones  and separate  doses for this summary table. 
In all cases, mice "cured" by treatment with immunogenic 
SaI/Ak/B7-1 cells had tumors that completely regressed after 
treatment, and the mice remained tumor-free for the entire 
period of observation (2.5-7 mo after SaI/N  challenge). 
Rejection  of SaI/B7-1  or  SaI/A~/B7-1  Tumor  by  Naive, 
Tumor-free Mice Requires CD4 + T Lymphocytes.  Previous ex- E 
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Figure  4.  Inoculation  of  transfec- 
tants into mice carrying larger 9-d es- 
tablished tumors.  A/J mice were inoc- 
ulated subcutaneously  in the flank on 
day 0 with  106 (A, B, E,  and F) or 
3 x  105 (C and D) wild-type SaI/N 
tumor cells, and left untreated  (A, C, 
and E) or 9 d later given a single injec- 
tion of 106 SaI/Ak/B7-1.12 cells (B and 
D), or 106 SaI/BT-1.36 cells (F). Par- 
allel untreated control groups were run 
concurrently  with each  experimental 
group (untreated controls in A, C, and 
E for treatment  groups in B, D, and F, 
respectively). Each line represents growth 
of an individual solid tumor in an in- 
dividual mouse. Cured mice remained 
tumor-flee for the 2.5-7-m0 observa- 
tion period  after  Sal/N challenge. 
periments  with  class  II §  transfected  SaI  tumor  cells  have 
demonstrated  that  mice depleted of CD4 + T  cells are un- 
able  to  reject  tumor,  suggesting  that  CD4 +  cells  are  re- 
quired for tumor resistance.  To determine if the immunity 
induced by B7-1 transfectants in tumor-free mice is also T 
cell-mediated, we have challenged sublethally irradiated (500 
fads) autologous A/J mice with  SaI/B7-1  or SaI/Ak/B7-1 
tumor cells.  In both cases,  immunocompromised mice de- 
veloped tumor (two out of two for each cell type), suggesting 
that  immunity  is T  cell  mediated.  To confirm  the role of 
CD4 § T cells, A/J mice were in vivo depleted of CD4 § T 
cells, and subsequently challenged with SaI/Ak/BT-1 tumor. 
As shown in Table 4, experiment 1, CD4-depleted mice de- 
velop tumor, while CD8-depleted mice do not. Development 
of immunity  in naive tumor-free mice to the class  II+B7 - 
1 + tumor therefore requires CD4 + T  lymphocytes, but ap- 
pears to be independent  of CD8 + T  cells. 
Immunotherapy of Mice Carrying Established SaI/N Tumors 
with SaI/Ak/B7-1  Cells Requires CD8 + T  Cells.  In  vivo 
depletion experiments have also been performed to identify 
the cells responsible for regression of established SaI/N tumors 
in SaI/Ak/B7-1-treated mice. Autologous A/J mice were in- 
oculated  subcutaneously with  106 SaI/N  cells,  and  subse- 
quently  treated  with  106 SaI/Ak/B7-1  cells  on days  13-19 
after  SaI/N  challenge.  At  the  time  of  treatment  with 
SaI/Ak/B7-1 cells, mice had solid tumors ranging from 4-8 
mm in diameter.  9 d before receiving the therapeutic  SaI/ 
Ak/B7-1 cells, the mice were started on the regimen of mAb 
depletion. Administration of mAbs was continued for 3-4 wk 
or until animals became moribund or tumors regressed. As 
shown in Table 4, experiment 2, mice treated with the ther- 
apeutic  SaI/Ak/B7-1  cells  and  either  undepleted,  CD4- 
depleted, or depleted with irrelevant mAb have a relatively 
low frequency of progressive tumor growth (38, 20,  20% 
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Figure  5.  Multiple  injections  of SaI/ 
Ak/B7-1  or  SaI/B7-1  cells  are  no  more 
effective than single injections in mediating 
tumor regression.  A/J mice were inocu- 
!ated subcutaneously in the flank on day 0 
with 3.3  ￿  10  s (.4 and B) or 106 (C and 
D) SaI/N cells and either untreated (71 and 
C)  or  given 5  x  105-106  SaI/B7-1.36 
cells on days 2, 11, 14, 23, 32, and 42 (B), 
or 4  x  10  s -106 Sal/A~/B7-1.12 cells intra- 
peritoneally on days 10, 15, 31, and 42 (D). 
Cured mice remained tumor-free for the 
2.5-7-mo observation period after SaI/N 
challenge. 
Table  3.  Summary Table of Mice Cured of Established SaI/N 
Tumors after Treatment with MHC Class II+ BT-1 + Transfectants 
Age  of 
SaI/N  tumor  No.  mice 
Initial dose  of  at  time of  Immunizing  cured/total 
SaI/N  tumor  treatment  tumor  treated 
10s-3.3  x  10  s 
106 
--  --  0/11 
9-13  d  SaI/Ak/B7-1  9/15 
2-13  d  SaI/B7-1  0/10 
-  -  0/14 
5-19  SaI/Ak/B7-1  19/33 
9  SaI/B7  0/10 
Mice were inoculated subcutaneously  in the flank with the indicated num- 
ber of SaI/N cells. Tumors were allowed to become established in vivo, 
and tumor-bearing mice were then treated by intraperitoneal inoculation 
with the indicated immunizing cells. SaI/N tumor growth was followed 
for at least  5 wk,  or until the tumors became >3 cm in diameter, at 
which time the mice were killed.  A "cured" mouse is a mouse in which 
the SaI/N tumor disappeared,  and the mouse remained tumor-free for 
at least 3 mo after treatment. Data are presented as pooled results of three 
(10  s  -  3.3  x  10  s group) or four (106 group) separate  experiments or 
experiments performed with different clones.  In all cases, individual ex- 
perimental groups showed the same partial responses seen in the pooled 
data. 
tumor  incidence  respectively),  while  100%  of untreated, 
unimmunized, or CDS-depleted, immunized mice have pro- 
gressively growing  tumor.  CD8 + T  cells  are therefore re- 
quired for successful immunotherapy  of established tumor, 
while CD4 + T  cells  are apparently not  involved. 
For Optimal Tumor Therapy, MHC Class II and B7-I Mole- 
cules Must Be Expressed on the Same Tumor Cell.  If coexpres- 
sion of MHC class II plus B7-1 molecules is to be used ther- 
apeutically, it would be useful to know if the two molecules 
must be expressed on the same cell, or if separate cell popula- 
tions, each expressing class II or B7-1, would be effective im- 
munogens.  Ideally we would test for complementation  of 
B7-1 and class II by challenging mice with a mixture of two 
sarcoma clones, each expressing either B7-1 or class II, and 
neither of which was immunogenic by itself. Since sarcoma 
cells expressing truncated MHC class II molecules are malig- 
nant and unable to deliver a costimulatory signal (4, 12), they 
can be used as the population delivering the antigen-specific 
signal. SaI/B7-1 cells will deliver a costimulatory signal, how- 
ever, they are themselves immunogenic (see Table 1). SaI/B7-1 
cells  are not,  however,  effective as rescuing cells  (see Figs. 
3,  4,  and  5),  and  hence  should  not  mediate  rejection  of 
SaI/Aktr  tumor  cells  unless  there  is  complementation  be- 
tween the SaI/Aktr  and SaI/B7-1  ceils. 
Complementation was tested by challenging A/J mice in- 
traperitoneally with a mixture  of 5  x  105 or 106 SaI/Aktr 
cells plus 5  x  105 or 106 SaI/B7-1 cells. As shown in Table 
5, admixtures of SaI/Aktr cells with SaI/B7-1 clone 36 cells 
625  Baskar et al. Table  4.  Immunity Induced by SaI/Ak/B7-1  Tumor Cells Requires  CD4 §  T  Lymphocytes  in Naive Mice, and CD8 §  T  Lymphocytes 
in  Tumor-bearing Mice 
Experiment  Challenge tumor  mAb depletion  Immunizing tumor  Tumor  incidence 
SaI/Ak/B7-1  -  -  0/10 
SaI/Ak/B7-1  anti-CD4 §  -  5/5 
SaI/Ak/B7-1  anti-CD8 +  -  0/5 
SaI/N  -  -  9/9 
Sal/N  -  SaI/Ak/B7-1  5/13 
SaI/N  anti-CD4 +  SaI/Ak/B7-1  1/5 
SaI/N  anti-CD8 +  SaI/Ak/B7-1  5/5 
SaI/N  irrelevant  IgG  SaI/Ak/B7-1  1/5 
In experiment 1,  autologous A/J mice were depleted for CD4 § or CD8 + T  cells before challenge with SaI/AUB7-1  tumor. In experiment 2,  SaI/N 
solid tumors were allowed to develop up to day 5  at  which time A/J hosts were depleted for CD4+  or CD8 §  T  cells, or treated with control 
irrelevant ascites mAb. In all cases, mice were maintained on depleting mAbs for 3-4 wk. Tumor inocula for SaI/AUB7-1  cells were 106 cells i.p.; 
for SaI/N  106 cells s.c. 
do  not  result  in  tumor  rejection,  while  three  clones  of 
SaI/Aktr/B7-1  cells  (clones  1,  3,  6)  are rejected.  Control 
tumor challenges confirm that the SaI/Aktr cells alone are 
malignant and that the SaI/B7-1 cells are rejected. If B7-1 
and MHC class II are presented on the same cell, however, 
(SaI/Aktr/B7-1 clone 1,  6,  or 12)  then rejection or partial 
rejection of the admixed SaI cells occurs. Optimal induction 
of tumor-specific immunity via coexpression of MHC class 
II plus B7-1 molecules therefore requires the presence of MHC 
class II and B7-1  molecules on the same tumor cell. 
Table  5.  MHC Class II and B7-1  Molecules Must Be 
Expressed on  the Same  Tumor Cell  to Stimulate  Tumor-specific 
Immunity. 
Challenge tumor(s)  Tumor incidence* 
SaI  (5  x  105  or  10  6) 
SaI/Aktr  (5  x  105  or  10  6) 
SaI/Aktr/B7-1.1 
SaI/Aktr/B7-1.3  (106) 
SaI/Aktr/B7-1.6 
SaI/B7-1.36  (106) 
SaI  +  SaI/Ak/B7-1.1 
SaI  +  SaI/Ak/B7-1.6 
SaI  +  SaI/AUB7-1.12 
SaI/Aktr  +  SaI/B7-1.36 
SaI/Aktr  (106)  +  SaI/B7-1.36  (106) 
14/15  (25 d) 
15/15  (25 d) 
0/5  (>49 d) 
1/14  (>42 d) 
0/5  (>5.5  mo) 
0/5  (>6 too) 
3/5  (>83 d) 
2/5  (>2 mo) 
0/5  (>2 mo) 
5/5  (25 d) 
5/5  (25 d) 
A/J mice were challenged with 5  x  10 s cells  i.p. unless noted other- 
wise. SaI/Aktr cells are clone 6-11-8 (12).  Some mice received a mix- 
ture of two tumor clones. Tumor incidence is the number of mice with 
tumor/total number of mice inoculated. 
* Number in parentheses indicates how long after tumor challenge the 
mice were followed for tumor incidence. 
Discussion 
Numerous recent studies have demonstrated that tumor 
cells transfected or transduced with certain cytokine or B7-1 
costimulatory genes become immunogenic (1-4,  15). Most 
of these studies, however, measure tumor immunogenicity 
by determining the tumorigenidty of the transfectants or trans- 
ductants, or their ability to immunize non-tumor-bearing 
mice against later challenges with wild-type tumor. In one 
study, Ib12-secreting fibroblasts given concommitantly with 
wild-type tumor significantly delayed the onset of tumor 
growth (16). Similar results were seen when 4T07 mammary 
carcinoma ceils were coinjected with  IL-2-secreting 4T07 
tumor (17). In only six studies have the transfectants/trans- 
ductants been used under the more stringent situation of 
treating mice with established tumor. In two of these studies, 
B7-1 + transfected melanoma cells coexpressing a strong viral 
antigen partially or completely blocked the development of 
melanoma metastases that had been induced 4-8 d before ad- 
ministration of the B7-1 transfectants (2, 18). In another study, 
injection of Ib4-secreting tumor ceUs into mice carrying small 
renal tumors (inoculation of 104 wild-type Renca cells given 
6 d before Ib4 transfectants) resulted in tumor regression (19). 
In a third study, injection of B16 melanoma transduced with 
GM-CSF into mice carrying 3-d established B16 tumors (initial 
inoculum of 5  x  104 B16 cells) resulted in significantly im- 
proved  survival.  The  GM-CSF-secreting  B16  ceils  were 
significantly less effective against the higher tumor inoculum 
of 10  s B16 cells (15). In another study, mice carrying estab- 
lished MBT2  bladder  tumors,  and  given an  inoculum of 
IL-2-secreting MBT2 cells on day 7 of primary tumor growth, 
showed significant reduction in tumor growth and extended 
survival (20). In the final study, treatment of 4-d established 
EL-4 tumors with BT-l-transfected EL4 cells resulted in tumor 
regression in 60% of treated mice (21). It is difiicult to quan- 
titatively compare the effectiveness  of these treatments be- 
cause different tumors having different growth rates were used. 
However, these studies dealt with small tumors that had been 
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(~<8 days).  In none of these studies using solid tumors were 
data presented demonstrating that the tumors were vascula- 
rized,  and hence truly established.  In contrast,  MHC class 
II+B7-1 + tumor cells  are highly effective in mediating re- 
gression of larger  tumors that  had proliferated in mice for 
up to 19 d. Although it is difficult to precisely compare the 
cytokine and class II,B7-1 therapy results because of the het- 
erogeneity of the tumors used in the different studies,  the 
class II +B7-1 + transfectants appear to be more effective im- 
munogens for the treatment of larger and longer-term estab- 
lished tumor. 
Recent studies by Chen et al. (21) indicate that the success 
of B7-1  in  costimulating  CD8 +  tumor-specific T  cell re- 
sponses is dependent on the inherent immunogenicity of the 
tumor.  They suggest that  coexpression of B7-1 by moder- 
ately or highly immunogenic tumors results in tumor rejec- 
tion,  while coexpression of B7-1 by poorly immunogenic 
tumors does not stimulate tumor rejection.  In our experi- 
ments, the SaI sarcoma behaves as a moderately immunogenic 
tumor. Immunity can be induced by irradiated wild-type SaI, 
however, it requires at least 50-fold more irradiated wild-type 
cells (5  X  10 6) than class II § transfectants (10  s or less). Fur- 
thermore, the immunity resulting from immunization with 
irradiated wild-type cells is only transient, while immuniza- 
tion with class II + transfectants yields 100% resistance for 
up to one year after immunization  (22). Because the wild- 
type SaI tumor is not highly immunogenic, our experiments 
suggest that tumor cells with a wide range of inherent  im- 
munogenicity may be candidates for this therapeutic approach. 
Clearly,  specific experiments with other moderately immuno- 
genic, poorly immunogenic,  and nonimmunogenic  tumors 
are necessary to definitively demonstrate the scope of effec- 
tiveness of class II +B7-1 + transfectants as therapy for estab- 
lished tumors. 
Expression  of B7-1  without  MHC class II converts the 
poorly immunogenic SaI sarcoma into an immunogenic tumor 
which is itself rejected by autologous A/J mice, and which 
is an effective vaccine against later challenge with wild-type 
tumor.  We previously reported that  an uncloned SaI/B7-1 
line was malignant in A/J mice (4). Our current results with 
SaI/B7-1 clones appear to contradict these earlier findings. 
We now believe that the uncloned SaI/B7-1 line of our original 
report was malignant because many of the cells downregu- 
lated B7-1 expression in vivo, and hence the line became a 
mixture of SaI and SaI/B7-1 cells. Inoculation of the SaI/B7-1 
line is therefore similar to a cell mixture experiment of SaI 
plus SaI/B7-1.36 in which five out of five inoculated mice 
die from tumor (Baskar,  S., and S. Ostrand-Rosenberg,  un- 
published results). The SaI/B7-1 clones used in the present 
experiments were chosen for their stable expression of B7-1. 
Although SaI/B7-1 cells are immunogenic in naive mice, when 
used as a therapeutic agent to treat mice carrying established 
solid tumors,  they have no effect, while SaI/Ak/B7-1  cells 
cause regression of wild-type established tumor.  Rejection 
of an established tumor probably requires a more rigorous 
immune response than rejection of a freshly inoculated tumor. 
Likewise, immunization of a host against a later tumor chal- 
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lenge provides time to generate immunity in the absence of 
malignant  tumor,  and hence rejection of wild-type tumor 
by preimmunized  mice is probably not as difficult as rejec- 
tion of established tumors.  SaI/B7-1 cells therefore induce 
immunity in non-tumor-bearing hosts, but are unable to in- 
duce sufficient immunity in tumor-bearing mice. In contrast, 
SaI/Ak/B7-1 cells appear to stimulate an immune response 
which is effective in mice carrying  high  tumor loads. 
It is likely that the additional effectiveness of SaI/Ak/B7-1 
vs SaI/B7-1 cells is because SaI/Ak/B7-1 cells can potentially 
stimulate  CD4 + and  CD8 + T  cells,  while SaI/B7-1  cells 
potentially stimulate only CD8 § T  cells. B7-1 is known to 
provide  costimulation  for  activation  of both  CD4 +  and 
CD8 § T  cells (14,  23). Activation of CD4 § T  cells occurs 
if the B7-1  signal is delivered in conjunction with antigen 
presented by MHC class  II,  while  activation  of CD8 + T 
cells occurs if the B7-1 signal is delivered in conjunction with 
antigen presented by MHC class I. Although the K1735 tumor 
cells used in the studies of Chen et al. (2) and Townsend and 
Allison (3) definitely express MHC class I molecules, their 
expression of MHC class  II molecules is unclear.  Chen  et 
al. (2) do not specify if their K1735 variant expresses class II, 
while Townsend and Allison (3) state the tumor is class II +, 
however, data supporting  this assertion  are  not presented. 
Other investigators (24) as well as our own observations (Pat- 
terson, N., and S. Ostrand-Rosenberg, unpublished results) 
indicate K1735 cells do not express MHC class II molecules. 
These authors' findings that B7-1-transfected class I + K1735 
cells induce CD8 § T  cell-dependent immunity is therefore 
consistent with the model that in the absence of MHC class 
II expression the K1735 tumor directly activates CD8 + T 
cells and bypasses the generation of CD4 + T  cells.  A more 
effective immune response may develop, however, if tumor- 
specific  CD4 + T  cell help  is also generated.  Class II+B7 - 
l+-transfected tumor cells  that constitutively express class 
I may therefore stimulate a more potent immune response 
because  they  also  activate  CD4 +  tumor-specific  Th  lym- 
phocytes. 
The CD4 and CD8 depletion data presented in this report 
(Table  3),  support  the  hypothesis  that  the class  II+B7-1 § 
tumor transfectants activate both CD4 + and CD8 + tumor- 
specific T cells. However, these data also raise additional ques- 
tions about the mechanism by which the transfectants  in- 
duce a therapeutic  response.  The depletion data for naive, 
non-tumor-bearing mice dearly demonstrate the involvement 
of CD4 § T cells, while the depletion data for tumor-bearing 
mice demonstrate  a critical  role for  CD8 + T  cells.  Since 
wild-type class II-  tumor cells are rejected by immunized, 
tumor-free mice, it is not clear why CD8 § T  cells are not 
needed for this response. Likewise, immunotherapy of estab- 
lished tumor appears to be independent  of CD4 § T  cells, 
yet  class  II+B7-1 +  tumor  cells,  and  not  tumor  cells  ex- 
pressing B7-1 without class II, are able to mediate the effect. 
A trivial explanation for these results is that the mAb deple- 
tions were not complete, and that the small number of re- 
sidual CD4 § or CD8 + T  cells suffice for tumor rejection. 
Support for this explanation comes from two labs which re- 
cently demonstrated that 82 microglobulin knockout, CDS- deficient mice have <1%  of the normal levels of CD8 + T 
cells, but are fully capable of rejecting class I allogeneic tumors 
(25, 26). Extremely low levels of CD8 + T cells therefore can 
be very effective in mediating tumor rejection. In constrast, 
in the present  study the requirement  for CD4 + T  cells in 
tumor-free mice and CD8 § T  cells in tumor-bearing mice, 
suggests that these particular  lymphocytes are needed in greater 
than residual quantities. Regardless of the precise timing for 
involvement of CD4 § and CD8 + T  cells in immunotherapy 
by class  II+B7-1 +  tumor  cells,  both  of these lymphocyte 
populations appear to be required,  supporting  the hypoth- 
esis that the double transfectants  are efficient inducers of tumor 
immunity because they successfully activate both CD4 + and 
CD8 + tumor-specific T  cells. 
Liu and Janeway (27) demonstrated in an in vitro system 
that  maximal  CD4 §  T  cell activation  occurred when  the 
antigen-specific signal and the costimulatory signal were de- 
livered by the same APC. The mixed cell experiments of this 
report  (Table 5) confirm  the Liu and Janeway results,  and 
extend their  conclusions  to in vivo generated  immune re- 
sponses.  There are at least two explanations  for why both 
signals must be expressed on the same APC. (a) The timing 
of delivery of the antigen-specific and costimulatory signals 
may be critical, and unless the two molecules are on the same 
APC,  the timing requirement  may not be met.  (b) There 
may be steric considerations that prevent delivery of the two 
signals by different cells. Inasmuch as B7-1 levels are roughly 
equivalent on the various SaI/Ak/B7-1  and SaI/B7-1 trans- 
fectants  it  is  unlikely  that  B7-1 density differences are re- 
sponsible for the absence of sufficient T  cell activation by 
SaI/B7-1  cells. 
The finding that both the antigen-specific and costimula- 
tory signals must be on the same tumor cell also has implica- 
tions for tumor immunotherapy. If an immunization approach 
such as that described here is used clinically,  the immunizing 
cells must be a cell population that homogeneously expresses 
both molecules.  Strategies using third party cells such as fibro- 
blasts to deliver the costimulatory signal would therefore not 
have  a high  likelihood of success. 
Transfection of MHC class II and B7-1 genes into tumor 
cells was initially envisioned as enhancing tumor immunity 
by producing a tumor cell that could directly activate CD4 § 
T  helper ceils.  Although class II molecules usually present 
exogenously synthesized peptides, there are numerous examples 
in which class II molecules present endogenously synthesized 
peptides (28-30). With the tumor cell as the primary APC, 
ample tumor peptide would be available for presentation by 
endogenously synthesized class II, and costimulation through 
B7-1 would be readily provided. The finding that both class 
II and B7-1 molecules must be expressed on the same tumor 
cell, although not definitive,  is suggestive that the tumor cell 
is functioning directly in antigen presentation.  Conversely, 
if the transfected tumor cells are not the principal APC, but 
third  party  (i.e.,  host)  APC  are  involved,  then  the  B7-1 
costimulatory signal should be expressed on the host APC, 
and there should be no requirement for it on the tumor ceils. 
Although further experiments are required to ascertain the 
precise mechanism  by which  class  II+B7-1 +  transfectants 
stimulate immunity,  these cells are clearly highly effective 
immunogens,  and may have significant potential in future 
immunotherapy  strategies for the  treatment  of established 
tumors. 
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